1. Graham, F.L. and Hitt, M.M. (2007) Adenoviral Vectors in Gene Therapy. In: Encyclopedia of Life Sciences. John Wiley & Sons, Ltd: Chichester http://www.els.net/ [DOI: 10.1002/9780470015902.a0005737.pub2]

2. Shi, C.X., Graham, F.L., and Hitt, M.M. (2006). A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for mammaglobin promoter studies. J. Gene Med. 8, 442-51.

3. Hitt, M., Ng, P., and Graham, F.L. (2006). Construction and propagation of human adenovirus vectors. In “Cell Biology: A Laboratory Handbook” (J.E. Celis, ed.), Third edition, Academic Press, San Diego, CA.,Vol. 1, pp. 435-443.

4. Sadeghi, H. and Hitt, M.M. Transcriptional targeting of adenovirus vectors. Current Gene Therapy 5: 411-427, 2005.

5. Shi, C.X., Long, M.A., Liu, L., Graham, F.L., Gauldie, J., and Hitt, M.M. The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not normal non-mammary cells. Molecular Therapy 10:758-767, 2004.

6. Trudel, S., Trachtenberg, J., Toi, A., Sweet, J., Hua Li, Z., Jewett, M., Tshilias, J., Zhuang, L. H., Hitt, M., Wan, Y., Gauldie, J., Graham, F. L., Dancey, J., and Keith Stewart, A. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther 10: 755-763, 2003.

7. Putzer, B. M., Rodicker, F., Hitt, M. M., Stiewe, T., and Esche, H. Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model. Mol. Therapy 5: 405-412, 2002.

8. Shi, C. X., Hitt, M., Ng, P., and Graham, F. L. Superior Tissue-Specific Expression from Tyrosinase and Prostate-Specific Antigen Promoters/Enhancers in Helper-Dependent Compared with First-Generation Adenoviral Vectors. Hum. Gene Ther. 13: 211-224, 2002.

9. Palmer, K., Hitt, M., Emtage, P., Gyorffy, S., and Gauldie, J. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor activity. Gene Therapy 8:282-90, 2001.

10. Chen, Y., Emtage, P., Zhu, Q., Foley, R., Muller, W., Hitt, M.M., Gauldie, J., and Wan, Y.-H. Induction of ErbB-2/neu specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: Enhanced efficiency by co-transduction of gene encoding IL-12. Gene Therapy 8:316-23, 2001.


Patent:

Hitt, M., Shi, C.-X., Long, M., and Graham, F. 'Mammoglobin Promoter.' US patent application filed 19 August 2003, based on provisional patent no. 60/404,125, filed 19 August 2002.